<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.3.1" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>
<channel>
	<title>Comments on: Seattle Genetics at ASH 2007 - SGN-33 (part II)</title>
	<link>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/</link>
	<description>Biotech stock reviews</description>
	<pubDate>Wed, 15 Oct 2008 23:44:51 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.3.1</generator>
		<item>
		<title>By: Ohad Hammer</title>
		<link>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-84</link>
		<dc:creator>Ohad Hammer</dc:creator>
		<pubDate>Wed, 23 Jan 2008 10:59:13 +0000</pubDate>
		<guid>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-84</guid>
		<description>Thanks. Glad I could help.</description>
		<content:encoded><![CDATA[<p>Thanks. Glad I could help.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Yash</title>
		<link>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-83</link>
		<dc:creator>Yash</dc:creator>
		<pubDate>Wed, 23 Jan 2008 09:37:03 +0000</pubDate>
		<guid>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-83</guid>
		<description>Hi, 
   This post comparing SGN-33 and competitors is very helpful.</description>
		<content:encoded><![CDATA[<p>Hi,<br />
   This post comparing SGN-33 and competitors is very helpful.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Ohad Hammer</title>
		<link>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-9</link>
		<dc:creator>Ohad Hammer</dc:creator>
		<pubDate>Sat, 22 Dec 2007 08:39:42 +0000</pubDate>
		<guid>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-9</guid>
		<description>Hi Peter

It is not my field of experitse, but things don't look too good on that front,as the DSMB's decision doesn't leave a lot of room for the resumption of the trial.

Of course, anything can happen, but it seems like Cloretazine combined with araC (especially high dose araC) is not the ideal treatment for elderly AML.

It doesn't mean Cloretazine cannot be used for other conditions.

Ohad</description>
		<content:encoded><![CDATA[<p>Hi Peter</p>
<p>It is not my field of experitse, but things don&#8217;t look too good on that front,as the DSMB&#8217;s decision doesn&#8217;t leave a lot of room for the resumption of the trial.</p>
<p>Of course, anything can happen, but it seems like Cloretazine combined with araC (especially high dose araC) is not the ideal treatment for elderly AML.</p>
<p>It doesn&#8217;t mean Cloretazine cannot be used for other conditions.</p>
<p>Ohad</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Peter J. Balhar</title>
		<link>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-8</link>
		<dc:creator>Peter J. Balhar</dc:creator>
		<pubDate>Wed, 19 Dec 2007 18:17:38 +0000</pubDate>
		<guid>http://www.hammerstockblog.com/seattle-genetics-at-ash-2007-sgn-33-part-ii/#comment-8</guid>
		<description>What is your opinion with regard to the halted Phase III trial, involving Ara-C and Cloretazine?</description>
		<content:encoded><![CDATA[<p>What is your opinion with regard to the halted Phase III trial, involving Ara-C and Cloretazine?</p>
]]></content:encoded>
	</item>
</channel>
</rss>
